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Abstract
Background: AD is a progressive neurodegenerative disorder that is associated with the accumulation of two
different insoluble protein aggregates, Aβ plaques and hyperphosphorylated tau. This study aimed to investigate
the optimal acquisition and quantification of [18F]AV45 and [18F]AV1451 to image Aβ and tau, respectively, in
subjects with AD.
Fifteen subjects with early stage AD underwent a T1-weighted structural MRI and two dynamic PET scans to image
Aβ (60 min, [18F]AV45) and tau (120 min, [18F]AV1451). Both dynamic BPND and static SUVR outcome measures were
calculated and compared for 12 out of 15 subjects who completed 60 min of the Aβ PET scan and at least 110 min
of the tau PET scan. The SRTM and reference Logan graphical analysis were applied to the dynamic data to
estimate regional BPND values and SUVR ratios from the static data. Optimal acquisition windows were explored for
both the dynamic and static acquisitions. In addition, the spatial correlation between regional Aβ and tau signals
was explored.
Results: Both the SRTM and graphical analysis methods showed a good fit to the dynamic data for both Aβ and
tau dynamic PET scans. Mean regional BPND estimates became stable 30 min p.i. for [
18F]AV45 and 80 min p.i.
for [18F]AV1451.
Time stability analysis of static SUVR data showed that the outcome measure starts to become stable for scan
windows of 30–50 min p.i. for [18F]AV45 and 80–100 min p.i. for [18F]AV1451. The results from these time windows
correlated well with the results from the full dynamic analysis for both tracers (R2 = 0.74 for [18F]AV45 and R2 = 0.88
for [18F]AV1451). There was a high correlation between amyloid uptake estimate using both dynamic analysis
methods in thalamus and tau uptake in thalamus, hippocampus and amygdala.
Conclusions: Short static PET scans at appropriate time windows provided SUVR values which were in reasonable
agreement with BPND values calculated from dynamic scans using SRTM and reference Logan. These simplified
methods may be appropriate for classification and intervention studies, although caution should be employed
when considering interventional studies where blood flow and extraction could change.
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Background
Alzheimer’s disease (AD) is a progressive neurodegener-
ative disorder that is associated with the accumulation
of two different insoluble protein aggregates, amyloid-β
(Aβ) plaques and neurofibrillary tangles (NFTs) consist-
ing of hyperphosphorylated tau protein. Evidence sug-
gests that both Aβ and NFTs have known involvement
in AD together with other less explored contributors [1].
The pathophysiological process of AD begins years be-
fore the clinical symptoms appear [2–4] and this preclin-
ical phase provides an opportunity for therapeutic
intervention. Molecular imaging of Aβ and tau could
provide important tools for stratifying subjects in this
preclinical phase and assessing the impact of novel drug
therapies [5, 6].
Positron emission tomography (PET) radioligands are now
available to image both insoluble Aβ plaques and tau neuro-
fibrillary tangles relevant for AD [7]. Aβ imaging has been
feasible since 2004 [8] following the introduction of [11C]PiB
and a number of fluorinated Aβ radiotracers (Florbetapir
([18F]AV45), [18F]Florbetaben, [18F]Flutemetamol) that
have been approved by European medicines agency
(EMA) as well as food and drug agency (FDA). These
tracers are being used in clinical trials for stratification
and to assess Aβ levels pre and post therapy [6, 9]. More
recently, efforts have focused on developing tracers suit-
able for imaging tau [10].
Initial studies have demonstrated that there are radio-
tracers that bind to tau and provide signals that are con-
sistent with postmortem data [11–13]. One of the first
generation tau tracers that has demonstrated such sig-
nals is [18F]AV1451 ([18F]T807) with evident in vivo dif-
ferences between healthy controls and AD subjects that
generally reflect the expected spatial distribution of tau
in AD [14].
The data presented here, involving [18F]AV45 and
[18F]AV1451, were acquired as part of the pilot phase of
the UK medical research council-sponsored (MRC) deep
and frequent phenotyping study which aims to identify
stratification markers and markers of change in the pre-
clinical phase of AD subjects. The pilot phase aimed to
determine participants’ acceptability of extensive and re-
peated phenotyping, the practicality of this procedure
and to establish an optimal protocol for the main study.
This paper aims to assess the PET imaging data ac-
quired as part of the pilot study, including dynamic Aβ
and tau scans, to provide better understanding of the
data and working towards designing an efficient protocol
for the main study. Different acquisition (dynamic vs
static) and analysis procedures will impact on the out-
come measures derived and were investigated with this
data set. Full kinetic analysis of the dynamic PET scans
was performed using quantitative reference tissue ap-
proaches including the simplified reference tissue model
(SRTM) [15, 16] and reference Logan graphical analysis
[17] to derive the non-displaceable binding potential
(BPND). Additionally, the simpler static measure of stan-
dardized uptake value ratio (SUVR) was obtained from
these data at various time windows and compared
against the full dynamic quantification to assess outcome
measure stability and bias. Finally, the spatial relation-
ship between Aβ and tau was investigated across the
subjects that had been scanned.
Methods
Subjects
Fifteen subjects were included in the analysis, with a
diagnosis of mild AD (with no AD pathophysiological
evidence) according to national institute of aging-
Alzheimer’s association (NIA-AA) criteria [18–21], aged
between 54 and 83 years, with a mini mental state
examination (MMSE) score of 21–29 and a modified
Hachinski ischemic score (HIS) of less than 4 [22]. All
subjects underwent a series of assessments including
clinical, cognitive, gait and ophthalmological assess-
ments, as well as molecular markers in cerebrospinal
fluid (CSF), blood, urine, PET imaging, magnetic reson-
ance imaging (MRI), magnetoencephalography (MEG)
and electroencephalography (EEG). The study was ap-
proved by the institutional review board and all subjects
signed an informed consent form (ICF).
Image acquisition
All subjects underwent a 3D T1-weighted structural
MRI and two dynamic PET scans to image Aβ and tau
on separate days. Acquisitions were conducted in ac-
cordance with the international conference on harmon-
isation (ICH) guideline for good clinical practice (GCP)
and the ethical principles that have their origins in the dec-
laration of Helsinki. The institutional review board/ethics
committee reviewed and approved the protocol and ICFs
as well as any advertising and subject materials before any
subjects were enrolled. A written, signed and dated ICF
was provided before any protocol was performed.
The MRI scan was performed on a Siemens 3T Tim Trio
with a 32-channel phased array head coil. A 1 mm iso-
tropic whole-brain structural 3D T1-weighted MPRAGE
[23] was acquired using TI = 880 ms, TR = 2000 ms and
FA = 8° with a parallel imaging factor of 2 in 4 m: 54 s. For
the PET scans, subjects were positioned in the PET scanner
after the insertion of a venous cannula in an antecubital or
forearm vein, and a head-fixation device was used to
minimize head movement during data acquisition. The
PET scans were acquired on two Siemens PET/CT
(computed tomography) scanners (Hi-Rez Biograph 6 and
Biograph 6 TruePoint with TrueV, Siemens Healthcare,
Erlangen, Germany), though for consistency each sub-
ject had both of their PET scans on the same scanner.
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A low-dose CT scan was performed immediately before
each PET scan in order to estimate attenuation. Each
subject received a single intravenous bolus of [18F]AV45
(150 ± 24 MBq) for a 60 min Aβ PET scan and
[18F]AV1451 (163 ± 10 MBq) for a 120 min tau scan. The
dynamic images were reconstructed using a 2D filtered back
projection (FBP) algorithm resulting in a 128 × 128 matrix
with 2 mm isotropic voxels. Corrections were applied for
attenuation, randoms, scatter and radioactive decay.
Image analysis
Two different classes of image analysis approaches were
investigated in this study: static and dynamic. In both
approaches, the T1-weighted MRI scan was used to ob-
tain anatomical information for each subject. Each sub-
ject’s whole brain was extracted using the Oxford centre
for functional MRI of the brain (FMRIB) software library
(FSL) [24] brain extraction tool (BET) [25] and the cor-
responding grey matter probability maps were created
using statistical parametric mapping (SPM5) software
[26]. A template MRI (ICBM152 [27]) was then nonli-
nearly warped to subject’s MRI using SPM5 and the
resulting deformation was applied to a brain anatomical
atlas [28] consisting of 119 brain regions to obtain the
brain region boundaries for each subject. This individu-
alized atlas was used at a later stage to derive regional
tissue time activity data from the dynamic PET images.
The dynamic PET images (2 × 2 × 2 mm) were initially
motion corrected by rigidly registering each frame to a
reference frame (13–15 min p.i.) using mutual informa-
tion and subsequently rigidly transformed into alignment
with the MRI and individualized atlas. The chosen refer-
ence frame contains both information on delivery and
uptake allowing for both early and late frames to be
aligned effectively. Finally, to be able to calculate differ-
ent parameters, the atlas in the individualized Montreal
neurological institute (MNI) space is down-sampled to
match PET voxel size.
Regional time activity curves (TACs) were generated
using the atlas and dynamic PET images. The SRTM
and reference Logan graphical analysis with cerebellum
grey matter as reference region were applied to the re-
gional TACs to estimate the BPND, used to quantify the
amount of tracer binding to the target proteins. Para-
metric images for both measures were also created by
applying the models to each voxel [16].
The SRTM model equation is given by,
CT tð Þ ¼ R1CR tð Þ þ k2− R1k21þ BPND
 
CR tð Þ  e−
−k2
1þBPNDð Þ t
ð1Þ
where CT(t) is the activity concentration in the target
tissue, CR(t) is the activity in reference tissue, k2 is the
efflux rate constant from target tissue, R1 is the ratio of
the delivery in target region to reference region. R1, k2
and BPND are estimated for each region.
The reference Logan graphical analysis method is
given by,
R t
0 CT sð Þds
CT tð Þ ¼ 1þ BPNDð Þ
R t
0 CR sð Þds
CT tð Þ þ int for t > t
ð2Þ
where BPND is the binding potential, ‘int’ is the regres-
sion intercept and t* is the equilibrium time.
The distribution of estimated regional BPND values
using the two reference tissue analysis methods from tau
and Aβ PET scans over all subjects was compared to as-
sess the performance of each method.
For the static analysis, SUVR values (Eq. 3) were
calculated using cerebellum grey matter as the reference
region. Regional average SUVR values were calculated
for 20 min time windows for a range of different start
times post injection (p.i.) (between 0 and 60 min for
[18F]AV45 and between 0 and 120 for [18F]AV1451)
from static images created by averaging the frames in
each time window.
SUVR tð Þ ¼ SUVTarget tð Þ
SUVReference tð Þ ð3Þ
where SUVTarget is the SUV of the target region and
SUVReference is the SUV of the reference region.
Additionally, the time stability of both dynamic (BPND)
and static (SUVR) outcome measures and their relation-
ship were investigated. The BPND values were calculated
for several scan durations by reducing the scan duration
with steps of 10 min and the SUVR values were calcu-
lated for 20 min time windows created by splitting the
scan period into 20 min time windows. The relation be-
tween these two measures was assessed by performing a
regression analysis. Additionally, the correlation between
regional Aβ and tau signals was explored.
All the above mentioned analysis was performed using
molecular imaging and kinetic analysis toolbox (MIA-
KAT™, version 4.0.2, http://www.miakat.org/MIAKAT2/
index.html).
Results
All subjects successfully completed the 60 min Aβ PET
scans and 12 out of 15 completed at least 110 min of the
tau PET scan—these 12 subjects were included in the
analysis that is presented here. The included subjects
had an average age of 71.4 ± 10.1, modified HIS score of
0.8 ± 1.0, mild cognitive impairment with MMSE score
of 24.3 ± 2.1 and Alzheimer’s disease assessment scale-
cognitive (ADAS-Cog) score of 15.5 ± 7.1. Mean symp-
tom duration was 3.5 ± 2.1 years and mean time since
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the initial diagnosis was 1.3 ± 2.1 years which was con-
firmed as an inclusion criteria at the time of the PET
scan.
Dynamic analysis
TACs and SRTM (Eq. 1) kinetic fits were successfully
generated for all 119 atlas regions of interest (ROIs) for
both Aβ and tau dynamic PET scans for all subjects. The
SRTM with cerebellum grey as reference region was fit-
ted to the TACs for each region (Fig. 1a, b) and the three
parameters (R1, k2 and BPND) were estimated per region.
The TACs show that the tau signal from [18F]AV1451
has slower kinetics and less regional distinction in
comparison to the Aβ signal from [18F]AV45. Similarly,
reference Logan graphical analysis (Eq. 2) with
cerebellum grey as reference tissue was fitted to the
TACs (Fig. 1c, d) and the two parameters (BPND and int)
were estimated per atlas region for each subject. Both
models showed a good fit to the data for both Aβ and
tau dynamic PET scans.
To investigate the approximate time at which regional
BPND values stabilize, the mean regional BPND values
derived using SRTM averaged over all subjects was plot-
ted against scan duration for both Aβ and tau dynamic
PET scans (Fig. 2a, b). Mean regional BPND estimates
become stable after 30 min p.i. for [18F]AV45 and after
80 min p.i. for [18F]AV1451 for all regions. Similar ana-
lysis was performed to the same PET scans using refer-
ence Logan graphical analysis model with cerebellum
grey as reference region and mean regional BPND values
were estimated for all subjects using a range of starting
time points (t*) for the regression analysis (Fig. 2c, d).
For t* values of over 30 min, the BPND values are stable
for Aβ scans, whereas stability occurs at t* greater than
70 min for tau. The estimated regional BPND values
using the two dynamic models were compared over all
subjects for Aβ and tau dynamic PET scans (Fig. 3).
Similar regional BPND values were estimated by both
dynamic models but overall, the regional BPND values
estimated by SRTM were higher on average with larger
variation across subjects.
Static analysis
The static analysis involved the calculation of regional
SUVR values for 20 min scan windows spanning the full
scan duration using Eq. 3 with the grey matter cerebellum
as the reference region. The time stability of mean regional
SUVR was assessed for several regions for all subjects
(Fig. 4) for Aβ and tau PET scans which showed that the
Fig. 1 SRTM (a, b) and reference Logan graphical analysis model (c, d) fit (solid line) to TACs (circles) of three example ROIs with different activity
levels for Aβ (a, c; t* = 20) and tau (b, d; t* = 50) dynamic PET scans
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Fig. 2 Estimated mean (the circles) and variation (vertical bars) of regional BPND values using SRTM (a, b) and reference Logan graphical analysis
(c, d) with cerebellum grey as reference region for three example regions over all subjects for Aβ (a, c) and tau (b, d) dynamic PET scans. t* indicates
the starting time of reference Logan graphical analysis
Fig. 3 Estimated regional BPND values using SRTM and reference Logan graphical analysis with cerebellum grey as reference region across all
subjects for selected regions for Aβ (a) and tau (b) dynamic PET scans. The BPND values estimated by reference Logan graphical analysis are for
optimum t* values (t* = 20 for Aβ and t* = 50 for tau)
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values became stable for scan windows of ~ 30–50 min
p.i. for [18F]AV45 and ~ 80–100 min p.i. for [18F]AV1451.
To investigate the relationship between the dynamic
and static measures, the coefficient of determination
(R2) was calculated for all atlas regions across all sub-
jects between BPND values, obtained from SRTM and
reference Logan graphical analysis methods, and SUVR
values of several 20 min time windows. The relationship
between these two outcome measures started to stabilize
from scan windows of ~ 40–60 min p.i. for [18F]AV45
and ~ 80–100 min p.i. for [18F]AV1451. The linear regres-
sion analysis of the regional BPND and SUVR values for the
above mentioned time windows showed a high correlation
between the two measures using both dynamic methods for
both Aβ (SUVR40− 60 = 0.97 × BPND_SRTM− 1.2, R
2
SRTM =
0.75; SUVR40 − 60 = 1.11 × BPND_Logan − 1.3, R
2
Logan = 0.7;
p < 0.01) and tau (SUVR80 − 100 = 1.028 × BPND_SRTM −
1.13; R2SRTM = 0.88; SUVR80 − 100 = 1.27 × BPND_Logan −
1.25; R2Logan = 0.71; p < 0.01) PET scans.
Correlation between Aβ and tau tracer signals
The correlation between estimated regional Aβ and tau
tracer signals using each of SRTM, reference Logan graph-
ical analysis and SUVR was explored. Twelve different atlas
regions with potential of having high Aβ and tau uptake
were selected based on the literature and R2 was calculated
for each outcome measure (BPND or SUVR) for all selected
region pairs (Fig. 5). In particular, for the quantitative dy-
namic analysis methods (SRTM and reference Logan), Aβ
signal in the thalamus was highly correlated with tau signal
in thalamus (R2SRTM = 0.76, R
2
RefLogan = 0.84, p < 0.05),
hippocampus (R2SRTM = 0.74, R
2
RefLogan = 0.73, p < 0.05) and
amygdala (R2SRTM = 0.56, R
2
RefLogan = 0.55, p < 0.05). For
SUVR, whilst the overall pattern of correlations was
similar, R2 was reduced (hippocampus: R2SUVR = 0.58, thal-
amus: R2SUVR = 0.46 and amygdala: R
2
SUVR = 0.57). The
tracer uptake pattern in whole brain, for both [18F]AV45
and [18F]AV1451, are shown in Fig. 6 for all 12 subjects
who completed full 60 min of the Aβ PET scan and at least
110 min of the tau PET scan. Overall, the tau signal was
very low in all subjects but there was a strong signal ob-
served in the striatal areas. Amyloid signal on the other
hand was strong in all brain regions and was not directly
related to MMSE scores (R2 = 0.006).
Discussion
In this paper, we assessed the dynamic behaviour of
[18F]AV45 and [18F]AV1451 targeting Aβ and tau pro-
teins respectively in early AD subjects by estimating re-
gional BPND values from dynamic PET scans using
SRTM and reference Logan graphical analysis models
with cerebellum grey as the reference region.
For the data presented here, arterial input functions
were not available and therefore we considered SRTM
results from full dynamic data as the reference standard
based on previous studies [29, 30]. Comparison of the
two dynamic analysis methods (SRTM and reference
Logan graphical analysis) showed that they produced
similar results with reference Logan graphical analysis
slightly underestimating the BPND values.
Time stability analysis of both tracers demonstrated that
stable estimates of the dynamic acquisition outcome par-
ameter BPND could be obtained with a minimum
acquisition time of 30 min for [18F]AV45 and 80 min for
[18F]AV1451. Time stability analysis of the SUVR ratio for
static acquisition scenarios indicated that the ratio became
reasonably constant in scanning windows of 30–50 min p.i.
for [18F]AV45 and 80–100 min p.i. for [18F]AV1451 and
Fig. 4 Time stability of mean SUVR values over all subjects with cerebellum grey as reference region for 20 min time windows over the whole
scan duration for Aβ (a) and tau (b) scans for three example regions
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were well correlated with the full dynamic SRTM results
across regions and subjects (R2 = 0.74 and R2 = 0.88, re-
spectively) [31, 32]. These results are consistent with the
faster kinetics of [18F]AV45 as compared to [18F]AV1451.
These results demonstrate that short static acquisitions,
whilst reducing subject time in the scanner and improving
compliance and feasibility, can derive semi-quantitative
outcome measures that can be used for classification of
subjects. Their use in longitudinal and intervention stud-
ies requires a little more caution as SUVR is not com-
pletely independent of blood flow changes [33].
Given the regional binding values for both tracers
([18F]AV45 and [18F]AV1451) in all subjects using
SRTM, it was possible to explore the correlations be-
tween [18F]AV45 and [18F]AV1451 uptake in different
brain regions. In this pilot data set, there was a high
correlation between [18F]AV45 uptake in thalamus and
[18F]AV1451 uptake in hippocampus. A degree of cau-
tion should be taken in interpreting these results given
the low level of amyloid in the thalamus and issues with
[18F]AV1451 due to off-target binding and possible spill-
over from the choroid plexus into the hippocampus.
Nevertheless, from a biological stand point, the neuro-
pathology literature [34] shows that dual amyloid and tau
changes in the thalamus mirror those in the hippocampus.
In addition, the changes in the thalamus affect prefer-
entially those nuclei with hippocampal connections.
Therefore, the current results, while speculative and
potentially accounted for by off-target binding, sug-
gest that linked thalamus-hippocampus dual pathology
reported in neuropathology studies may be demon-
strable using PET scans. Thus, it would be important
Fig. 5 Signed coefficient of determination (R2) of regional BPND values derived using SRTM (a), reference Logan graphical analysis (b) and SUVR
(c) methods for 12 regions with high potential for Aβ or tau uptake (The values between − 0.3 and 0.3 are masked for easier interpretation)
Fig. 6 [18F]AV45 (top row) and [18F]AV1451 (bottom row) uptake patterns in whole brain represented by BPND values estimated using SRTM for all
subjects who completed full 60 min of Aβ and at least 110 min of tau PET scan. Subjects are ordered based on their MMSE scores
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to replicate these results with an improved tau tracer
and in a larger cohort of subjects.
Whilst, [18F]AV45 and other EMA- and FDA-approved
radiotracers have been shown to be highly selective for
amyloid, the first generation of tau tracers, including
[18F]AV1451, have demonstrated some off-target binding.
Much of the off-target binding of putative tau agents has
focused on monoamine oxidase (MAO) with [18F]AV1451
demonstrating some clear subcortical signals due to its
binding to MAO-A [35, 36]. Thus, the interpretation of
any subcortical [18F]AV1451 signal should be treated with
a degree of caution. Other first generation tau tracers,
such as [18F]THK5351 ([18F]GE216) [37, 38], have shown
even more substantial problems with a large amount of
off-target binding to MAO-B that also compromises the
interpretation of cortical regions [35]. Second generation
tau tracers are now just appearing with [18F]GTP1 [39],
[18F]RO6958948 [40] and [18F]MK6240 [41] all demon-
strating cleaner signals with increased selectivity for tau.
Conclusions
Based on the data presented, short (20 min) static PET
scans at appropriate time windows provide SUVR values
which are in reasonable agreement with BPND values calcu-
lated from dynamic scans using SRTM. Appropriate scan
window choices for [18F]AV45 are 30–50 or 40–60 min p.i.,
and for [18F]AV1451 are 80–100 or 90–110 min p.i. based
on the desired accuracy and logistics. Care should be
taken to determine whether this outcome measure is
optimal in interventional studies.
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